AstraZeneca

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 34
Average round size
info
The average size of a deal this fund participated in
$64M
Portfolio companies 28
Rounds per year 1.48
Lead investments 4
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 8
Key employees 30

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Non Profit
  • Therapeutics
Summary

AstraZeneca appeared to be the Corporate Investor, which was created in 1999. The main department of described Corporate Investor is located in the Cambridge. The company was established in North America in United States.

We also calculated 29 valuable employees in our database.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the AstraZeneca, startups are often financed by Auven Therapeutics, New Enterprise Associates, Johnson & Johnson Development Corporation. The meaningful sponsors for the fund in investment in the same round are Auven Therapeutics, Redmile Group, Novartis. In the next rounds fund is usually obtained by Auven Therapeutics, Viking Global Investors, Redmile Group.

The common things for fund are deals in the range of 50 - 100 millions dollars. Considering the real fund results, this Corporate Investor is 2 percentage points less often commits exit comparing to other organizations. The high activity for fund was in 2014. Despite it in 2019 the fund had an activity. The fund is generally included in 2-6 deals every year. The average startup value when the investment from AstraZeneca is more than 1 billion dollars. The higher amount of exits for fund were in 2018. Opposing the other organizations, this AstraZeneca works on 11 percentage points less the average amount of lead investments.

Among the most successful fund investment fields, there are Health Care, Biopharma. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Moderna Therapeutics, FibroGen, Rani Therapeutics. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of AstraZeneca:
Typical Co-investors
AstraZeneca is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after AstraZeneca:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Brait Central Region, Malta, NA - Malta
Calao Finance France, Ile-de-France, Paris
Cook Pharmica, LLC Bloomington, Indiana, United States
Huaxing Alpha New York, New York, United States
Inmobiliaria e Inversiones el Coigue Chile, Santiago Metropolitan Region, Vitacura
McConnell Foundation Canada, Montreal, Quebec
MRI Ventures Kansas City, Missouri, United States
Pearl Energy Investments Dallas, Texas, United States
Sumavision Beijing, Beijing, China
Yushan Ventures Taipei, Taiwan

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Huma

Big Data
Biotechnology
Health Care
Information Technology
Insurance
Management Information Systems
mHealth
Pharmaceutical
Sports
Wearables
Wellness
$34M23 Mar 2022 London, England, United Kingdom

Cellular Biomedicine Group

Biotechnology
Medical Device
Therapeutics
$120M28 Sep 2021 Palo Alto, California, United States

OnDosis

Pharmaceutical
$3M11 Sep 2020 Sweden, Västra Götaland County, Sweden

ADC Therapeutics

Biopharma
Biotechnology
Medical
Therapeutics
$82M12 Jun 2019 Lausanne, Vaud, Switzerland

Innate Pharma

Biopharma
Biotechnology
Clinical Trials
Medical
Pharmaceutical
$73M24 Oct 2018 Provence-Alpes-Côte d'Azur

PhaseBio Pharmaceuticals

Biotechnology
Medical
Medical Device
Pharmaceutical
$34M05 Sep 2018 Pennsylvania, United States

Biopharma
Biotechnology
Health Diagnostics
Medical
Wellness
$282M28 Feb 2018 Maryland, United States

Rani Therapeutics

Biotechnology
Pharmaceutical
Therapeutics
$53M07 Feb 2018 San Jose, California, United States

ADC Therapeutics

Biopharma
Biotechnology
Medical
Therapeutics
$200M23 Oct 2017 Lausanne, Vaud, Switzerland

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent AstraZeneca?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: